Phaseline

Targets › MSTN

MSTN (Growth/differentiation factor 8): drug programs, companies and trials

3 programs from 3 companies in 8 trials: 6 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Nov 2026.

Acts specifically as a negative regulator of skeletal muscle growth. (UniProt, O14793)

Open in Phaseline: the race on MSTN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Scholar RockApitegromab
Growth/differentiation factor 8 inhibitor
MSTNPhase 3Spinal Muscular Atrophy; Facioscapulohumeral Muscular DystrophyJun 2028
RocheRO7204239
Anti-myostatin antibody
MSTNPhase 2Facioscapulohumeral Muscular Dystrophy (FSHD); Spinal Muscular Atrophy (SMA); Obesity; Type 2 Diabetes MellitusNov 2026
Regeneron PharmaceuticalsTrevogrumab
GDF8 (myostatin) inhibitor
MSTNPhase 2Obesity–

Conditions

Spinal Muscular Atrophy (2) Obesity (2) Facioscapulohumeral Muscular Dystrophy (1) Facioscapulohumeral Muscular Dystrophy (FSHD) (1) Spinal Muscular Atrophy (SMA) (1) Type 2 Diabetes Mellitus (1)

Modalities

mixed (2), small molecule (1)

Companies

Scholar Rock (1) Roche (1) Regeneron Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.